Are you Dr. Sitz?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 52 invites waiting! - Read the latest clinical news, personalized to your specialty.
Office
18 Corporate Hill Dr
Ste 110
Little Rock, AR 72205Phone+1 501-224-1156Fax+1 501-801-5561
Summary
- Dr. Karl Sitz, MD is an allergist/immunologist in Little Rock, Arkansas. He is currently licensed to practice medicine in Arkansas. He is affiliated with CHI St. Vincent Infirmary.
Education & Training
- National Capital ConsortiumFellowship, Allergy and Immunology, 1990 - 1992
- University of Arkansas for Medical Sciences (UAMS) College of MedicineResidency, Internal Medicine, 1986 - 1989
- University of Arkansas For Medical Sciences College of MedicineClass of 1986
Certifications & Licensure
- AR State Medical License 1986 - 2026
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Clinical & Laboratory Immunology
Clinical Trials
- Observational Safety Study for KALBITOR (Ecallantide) in the Treatment of Acute Attacks of Hereditary Angioedema Start of enrollment: 2010 Feb 01
- Extensively Hydrolyzed Formula: Hypoallergenicity Start of enrollment: 2011 Feb 01
Publications & Presentations
PubMed
- 3 citationsLigelizumab improves angioedema, disease severity and quality-of-life in patients with chronic spontaneous urticaria.Martin Metz, Jonathan A Bernstein, Ana M Giménez-Arnau, Michihiro Hide, Marcus Maurer
The World Allergy Organization Journal. 2022-11-01 - 25 citationsSustained safety and efficacy of ligelizumab in patients with chronic spontaneous urticaria: A one-year extension study.Marcus Maurer, Ana Giménez-Arnau, Jonathan A. Bernstein, Chia-Yu Chu, I V Danilycheva
Allergy. 2021-11-22 - 75 citationsOral once-daily berotralstat for the prevention of hereditary angioedema attacks: A randomized, double-blind, placebo-controlled phase 3 trialBruce L. Zuraw, William R. Lumry, Douglas T. Johnston, Emel Aygören-Pürsün, Aleena Banerji
The Journal of Allergy and Clinical Immunology. 2020-10-21